Boston Scientific Corporation reported interim data from the REDUCE-HTN clinical program, which demonstrated a significant and sustained reduction in the blood pressure of patients treated with the Vessix Renal Denervation System. Data on the first 41 subjects enrolled in the REDUCE-HTN clinical program were presented today at the annual EuroPCR Scientific Program in Paris by Joachim Schofer, M.D., of the Hamburg University Cardiovascular Center.

Data presented at Heart Rhythm 2013 show that Medtronic Inc. Lead Integrity Alert (LIA) software detected pace/sense lead issues in non-Medtronic leads at a greater rate than standard impedance monitoring alone (impedance monitoring measures the electrical continuity of a lead four times per day). The retrospective analysis, which focused on Endotak leads (Boston Scientific) and was presented by Kenneth Ellenbogen, M.D., shows that for every one Endotak pace/sense lead issue detected by impedance monitoring, the LIA software detected four cases that impedance monitoring alone missed. LIA is not currently FDA approved for use with non-Medtronic leads.

The Medicare trustees have projected that the trust fund that finances Medicare’s hospital insurance coverage will remain solvent until 2026, two years beyond what was projected in last year’s report.

June 4, 2013 — During the 2013 Annual Meeting of the Society for Imaging Informatics in Medicine (SIIM), DR Systems will demonstrate its DR Systems Unity Enterprise Imaging Excellence Solution, e|HR for Meaningful Use and eMix, and electronic medical information exchange